title: The effect of citalopram hydrobromide on 5-HT2A receptors in the impulsive-aggressive dog, as measured with 123I-5-I-R91150 SPECT.
abstract: OBJECTIVE
  Involvement of the serotonergic system in impulsive aggression has been demonstrated in both human and animal studies. The purpose of the present study was to investigate the effect of citalopram hydrobromide (a selective serotonin re-uptake inhibitor) on the 5-HT(2A) receptor and brain perfusion in impulsive-aggressive dogs by means of single-photon emission computed tomography.
  
  
  METHODS
  The binding index of the radioligand (123)I-5-I-R91150 was measured before and after treatment with citalopram hydrobromide in nine impulsive-aggressive dogs. Regional perfusion was measured with (99m)Tc-ethyl cysteinate dimer (ECD). Behaviour was assessed before treatment and again after 6 weeks of treatment.
  
  
  RESULTS
  A correlation was found between decreased binding and behavioural improvement in eight out of nine dogs. The 5-HT(2A) receptor binding index was significantly reduced after citalopram hydrobromide treatment in all cortical regions but not in the subcortical area. None of the dogs displayed alterations in perfusion on the post-treatment scans.
  
  
  CONCLUSIONS
  This study supports previous findings regarding the involvement of the serotonergic system in impulsive aggression in dogs in general. More specifically, the effect of treatment on the 5-HT(2A) receptor binding index could be demonstrated and the decreased binding index correlated with behavioural improvement.
authors.affiliation: Department of Medical Imaging, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 9820, Merelbeke, Belgium. kathelijne.peremans@ugent.be
authors.forename: K
authors.initials: K
authors.lastname: Peremans
authors.forename: K
authors.initials: K
authors.lastname: Audenaert
authors.forename: Y
authors.initials: Y
authors.lastname: Hoybergs
authors.forename: A
authors.initials: A
authors.lastname: Otte
authors.forename: I
authors.initials: I
authors.lastname: Goethals
authors.forename: I
authors.initials: I
authors.lastname: Gielen
authors.forename: P
authors.initials: P
authors.lastname: Blankaert
authors.forename: M
authors.initials: M
authors.lastname: Vervaet
authors.forename: C
authors.initials: C
authors.lastname: van Heeringen
authors.forename: R
authors.initials: R
authors.lastname: Dierckx
mesh_terms: D000374:Aggression / Q000187:drug effects; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001921:Brain / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000378:metabolism*; D015283:Citalopram / Q000008:administration & dosage*; D004285:Dogs; D007175:Impulsive Behavior / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000378:metabolism*; D010880:Piperidines / Q000493:pharmacokinetics*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D044402:Receptor, Serotonin, 5-HT2A / Q000378:metabolism*; D058830:Serotonin 5-HT2 Receptor Antagonists; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage; D014018:Tissue Distribution; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods; D016896:Treatment Outcome
chemical_list: D015283:Citalopram; D010880:Piperidines; D019275:Radiopharmaceuticals; D044402:Receptor, Serotonin, 5-HT2A; D058830:Serotonin 5-HT2 Receptor Antagonists; D017367:Selective Serotonin Reuptake Inhibitors; C504893:5-iodo-R 91150
references.citation: Psychopharmacology (Berl). 2002 Jan;159(3):266-74
references.pmid: 11862359
references.citation: Neurosci Lett. 1994 Apr 25;171(1-2):183-6
references.pmid: 8084487
references.citation: Psychopharmacology (Berl). 2003 Apr;167(1):72-8
references.pmid: 12632246
references.citation: Physiol Behav. 2003 Nov;80(2-3):327-31
references.pmid: 14637232
references.citation: Am J Psychiatry. 1998 Apr;155(4):543-7
references.pmid: 9546002
references.citation: Psychopharmacology (Berl). 1999 Jun;144(3):279-81
references.pmid: 10435395
references.citation: Neuropharmacology. 2000 Jan 28;39(3):471-81
references.pmid: 10698013
references.citation: Vet Clin North Am Small Anim Pract. 1997 May;27(3):479-95
references.pmid: 9170631
references.citation: Arch Gen Psychiatry. 1996 Jun;53(6):537-43
references.pmid: 8639037
references.citation: Biol Psychiatry. 2000 Mar 15;47(6):548-56
references.pmid: 10715361
references.citation: J Neuroendocrinol. 2003 Feb;15(2):150-60
references.pmid: 12535157
references.citation: Biol Psychiatry. 1999 Jun 15;45(12):1572-9
references.pmid: 10376117
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2001 Jul;25(5):1125-44
references.pmid: 11444681
references.citation: Psychopharmacology (Berl). 2003 May;167(3):304-14
references.pmid: 12677356
references.citation: Brain Res. 2003 Jun 20;976(1):22-9
references.pmid: 12763618
references.citation: Neuroscience. 1999;92(1):327-41
references.pmid: 10392854
references.citation: Arq Neuropsiquiatr. 2001 Sep;59(3-A):499-503
references.pmid: 11588625
references.citation: Psychopharmacology (Berl). 1997 Sep;133(1):99-101
references.pmid: 9335087
references.citation: Arch Gen Psychiatry. 1994 Jan;51(1):20-7
references.pmid: 7506515
references.citation: Nucl Med Commun. 2002 Oct;23 (10 ):1019-27
references.pmid: 12352602
references.citation: Neuroscience. 1987 Apr;21(1):123-39
references.pmid: 3601071
references.citation: Eur J Nucl Med. 2001 Feb;28(2):175-82
references.pmid: 11303887
references.citation: J Am Vet Med Assoc. 1996 Nov 1;209(9):1585-7
references.pmid: 8899022
references.citation: Psychopharmacology (Berl). 1999 Mar;143(1):24-8
references.pmid: 10227076
references.citation: Brain Res. 2002 Nov 8;954(2):173-82
references.pmid: 12414100
references.citation: Neuropsychopharmacology. 2002 Sep;27(3):421-9
references.pmid: 12225699
references.citation: J Nucl Med. 1998 Jan;39(1):208-14
references.pmid: 9443763
references.citation: Br J Psychiatry. 1998 Sep;173:236-41
references.pmid: 9926100
references.citation: J Neurosci. 1999 Dec 1;19(23):10494-501
references.pmid: 10575045
references.citation: Am J Psychiatry. 2001 Jan;158(1):78-85
references.pmid: 11136637
references.citation: Brain Res. 1985 Nov 4;346(2):231-49
references.pmid: 4052777
references.citation: Am J Psychiatry. 2001 Jun;158(6):899-905
references.pmid: 11384897
references.citation: Eur J Nucl Med Mol Imaging. 2003 Nov;30(11):1538-46
references.pmid: 14579095
references.citation: Pharmacol Biochem Behav. 1991 Dec;40(4):751-6
references.pmid: 1816562
references.citation: Eur J Nucl Med. 1997 Oct;24(10 ):1253-60
references.pmid: 9323266
references.citation: Brain Res. 1991 Sep 20;559(2):181-90
references.pmid: 1794096
references.citation: Vet Radiol Ultrasound. 2001 Nov-Dec;42(6):562-8
references.pmid: 11768526
references.citation: Psychiatry Res. 2003 Jul 15;119(1-2):11-24
references.pmid: 12860356
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 1995 Aug;352(2):141-8
references.pmid: 7477436
references.citation: J Clin Psychopharmacol. 2002 Aug;22(4):400-5
references.pmid: 12172340
references.citation: Arch Gen Psychiatry. 1997 Dec;54(12 ):1081-8
references.pmid: 9400343
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2000 Apr;24(3):419-38
references.pmid: 10836490
references.citation: Eur J Nucl Med. 1995 Jul;22(7):699-710
references.pmid: 7498234
references.citation: Brain Res. 1996 Apr 1;714(1-2):57-64
references.pmid: 8861609
references.citation: Neuropsychopharmacology. 2001 Apr;24(4):370-8
references.pmid: 11182532
references.citation: J Clin Psychiatry. 2003 Jan;64(1):81-5
references.pmid: 12590628
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2002 Dec;26(7-8):1393-404
references.pmid: 12502029
references.citation: Neuropsychopharmacology. 1996 Feb;14(2):77-81
references.pmid: 8822529
references.citation: Physiol Behav. 2003 Sep;79(4-5):719-24
references.pmid: 12954414
references.citation: J Clin Psychopharmacol. 2001 Feb;21(1):53-8
references.pmid: 11199948
references.citation: Eur J Pharmacol. 1995 Dec 29;294(2-3):721-6
references.pmid: 8750738